Hostname: page-component-586b7cd67f-2plfb Total loading time: 0 Render date: 2024-11-22T17:52:36.852Z Has data issue: false hasContentIssue false
  • English
  • Français

Systemic rapamycin to prevent in-stent stenosis in peripheral pulmonary arterial disease: early clinical experience

Published online by Cambridge University Press:  28 December 2015

Anna Hallbergson ,
Jesse J. Esch ,
Trang X. Tran ,
James E. Lock  and
Audrey C. Marshall
Anna Hallbergson
Affiliation:
Department of Cardiology, Boston Children’s Hospital and Department of Pediatrics, Harvard Medical School, Boston, Massachusetts, United States of America Children’s Heart Center, Skåne University Hospital, Lund, Sweden
Jesse J. Esch
Affiliation:
Department of Cardiology, Boston Children’s Hospital and Department of Pediatrics, Harvard Medical School, Boston, Massachusetts, United States of America
Trang X. Tran
Affiliation:
Department of Cardiology, Boston Children’s Hospital and Department of Pediatrics, Harvard Medical School, Boston, Massachusetts, United States of America
James E. Lock
Affiliation:
Department of Cardiology, Boston Children’s Hospital and Department of Pediatrics, Harvard Medical School, Boston, Massachusetts, United States of America
Audrey C. Marshall*
Affiliation:
Department of Cardiology, Boston Children’s Hospital and Department of Pediatrics, Harvard Medical School, Boston, Massachusetts, United States of America
*
Correspondence to: A. C. Marshall, MD, Department of Cardiology, Children’s Hospital of Boston, 300 Longwood Avenue, Boston, MA 02115, United States of America. Tel: +617 355 6529; Fax: +617 713 3808; E-mail: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

Objectives

We have taken a novel approach using oral rapamycin – sirolimus – as a medical adjunct to percutaneous therapy in patients with in-stent stenosis and high risk of right ventricular failure.

Background

Peripheral pulmonary artery stenosis can result in right ventricular hypertension, dysfunction, and death. Percutaneous pulmonary artery angioplasty and stent placement acutely relieve obstructions, but patients frequently require re-interventions due to re-stenosis. In patients with tetralogy of Fallot or arteriopathy, the problem of in-stent stenosis contributes to the rapidly recurrent disease.

Methods

Rapamycin was administered to 10 patients (1.5–18 years) with peripheral pulmonary stenosis and in-stent stenosis and either right ventricular hypertension, pulmonary blood flow maldistribution, or segmental pulmonary hypertension. Treatment was initiated around the time of catheterisation and continued for 1–3 months. Potential side-effects were monitored by clinical review and blood tests.

Results

Target serum rapamycin level (6–10 ng/ml) was accomplished in all patients; eight of the nine patients who returned for clinically indicated catheterisations demonstrated reduction in in-stent stenosis, and eight of the 10 patients experienced no significant side-effects. Among all, one patient developed diarrhoea requiring drug discontinuation, and one patient experienced gastrointestinal bleeding while on therapy that was likely due to an indwelling feeding tube and this patient tolerated rapamycin well following tube removal.

Conclusions

Our initial clinical experience supports that patients with peripheral pulmonary artery stenosis can be safely treated with rapamycin. Systemic rapamycin may provide a novel medical approach to reduce in-stent stenosis.

Keywords

In-stent stenosisrapamycintetralogy of Fallotperipheral pulmonary stenosisarteriopathy
Type
Original Articles
Information
Cardiology in the Young , Volume 26 , Issue 7 , October 2016 , pp. 1319 - 1326
Check for updates
Copyright
© Cambridge University Press 2015 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1. Bird, LM, Billman, GF, Lacro, RV, et al. Sudden death in Williams syndrome: report of ten cases. J Pediatr 1996; 129: 926–931.Google Scholar
2. Geggel, RL, Gauvreau, K, Lock, JE. Balloon dilation angioplasty of peripheral pulmonary stenosis associated with Williams syndrome. Circulation 2001; 103: 2165–2170.Google Scholar
3. Monge, MC, Mainwaring, RD, Sheikh, AY, Punn, R, Reddy, VM, Hanley, FL. Surgical reconstruction of peripheral pulmonary artery stenosis in Williams and Alagille syndromes. J Thorac Cardiovasc Surg 2013; 145: 476–481.Google Scholar
4. Maglione, J, Bergersen, L, Lock, JE, McElhinney, DB. Ultra-high-pressure balloon angioplasty for treatment of resistant stenoses within or adjacent to previously implanted pulmonary arterial stents. Circ Cardiovasc Interv 2009; 2: 52–58.Google Scholar
5. Law, MA, Shamszad, P, Nugent, AW, et al. Pulmonary artery stents: long-term follow-up. Catheter Cardiovasc Interv 2010; 75: 757–764.Google Scholar
6. Fogelman, R, Nykanen, D, Smallhorn, JF, McCrindle, BW, Freedom, RM, Benson, LN. Endovascular stents in the pulmonary circulation. Clinical impact on management and medium-term follow-up. Circulation 1995; 92: 881–885.CrossRefGoogle ScholarPubMed
7. Hallbergson, A, Lock, JE, Marshall, AC. Frequency and risk of in-stent stenosis following pulmonary artery stenting. Am J Cardiol 2014; 113: 541–545.Google Scholar
8. McMahon, CJ, El-Said, HG, Grifka, RG, Fraley, JK, Nihill, MR, Mullins, CE. Redilation of endovascular stents in congenital heart disease: factors implicated in the development of restenosis and neointimal proliferation. J Am Coll Cardiol 2001; 38: 521–526.Google Scholar
9. Mehran, R, Dangas, G, Abizaid, AS, et al. Angiographic patterns of in-stent restenosis: classification and implications for long-term outcome. Circulation 1999; 100: 1872–1878.Google Scholar
10. Simsek, C, Magro, M, Boersma, E, et al. The unrestricted use of sirolimus- and paclitaxel-eluting stents results in better clinical outcomes during 6-year follow-up than bare-metal stents: an analysis of the RESEARCH (Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital) and T-SEA. JACC Cardiovasc Interv 2010; 3: 1051–1058.CrossRefGoogle Scholar
11. Hausleiter, J, Kastrati, A, Mehilli, J, et al. Randomized, double-blind, placebo-controlled trial of oral sirolimus for restenosis prevention in patients with in-stent restenosis: the Oral Sirolimus to Inhibit Recurrent In-stent Stenosis (OSIRIS) trial. Circulation 2004; 110: 790–795.Google Scholar
12. Rodriguez, AE, Granada, JF, Rodriguez-Alemparte, M, et al. Oral rapamycin after coronary bare-metal stent implantation to prevent restenosis: the Prospective, Randomized Oral Rapamycin in Argentina (ORAR II) study. J Am Coll Cardiol 2006; 47: 1522–1529.Google Scholar
13. Waksman, R, Ajani, AE, Pichard, AD, et al. Oral rapamycin to inhibit restenosis after stenting of de novo coronary lesions: the Oral Rapamune to Inhibit Restenosis (ORBIT) study. J Am Coll Cardiol 2004; 44: 1386–1392.Google Scholar
14. Schubert, M, Venkataramanan, R, Holt, DW, et al. Pharmacokinetics of sirolimus and tacrolimus in pediatric transplant patients. Am J Transplant 2004; 4: 767–773.Google Scholar
15. Gupta, P, Kaufman, S, Fishbein, TM. Sirolimus for solid organ transplantation in children. Pediatr Transplant 2005; 9: 269–276.Google Scholar
16. Ettenger, RB, Grimm, EM. Safety and efficacy of TOR inhibitors in pediatric renal transplant recipients. Am J Kidney Dis 2001; 38: S22–S28.Google Scholar
17. Bergersen, L, Giroud, JM, Jacobs, JP, et al. Report from the International Society for Nomenclature of Paediatric and Congenital Heart Disease: cardiovascular catheterisation for congenital and paediatric cardiac disease (Part 2 – nomenclature of complications associated with interventional cardiology). Cardiol Young 2011; 21: 260–265.Google Scholar